Dr. Josef Thaler, Ph.D.

Publikovaná abstrakta

• A MULTICENTER, RANDOMIZED PHASE III STUDY OF RITUXIMAB AS MAINTENANCE TREATMENT VERSUS OBSERVATION ALONE IN PATIENTS WITH AGGRESSIVE B-CELL LYMPHOMA: THE AGMT NHL13 TRIAL
• Baseline Characteristics of CML Patients Accross Europe - Comparing Real-World Patients with Patient Collectives Included in Clinical Trials
• BORTEZOMIB-BENDAMUSTINE-DEXAMETHASONE (BBD) IN PATIENTS WITH RELAPSED/REFRACTORY MYELOMA AND DIFFERENT RISK PROFILES NAMELY, CYTOGENETICS, PREVIOUS EXPOSURE TO BORTEZOMIB OR TO LENALIDOMIDE
• BORTEZOMIB-BENDAMUSTINE-DEXAMETHASONE FOR TREATMENT OF RELAPSED/REFRACTORY MYELOMA
• Bortezomib-Bendamustine-Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma (MM) Shows Marked Efficacy and Is Well Tolerated, but Assessment of PNP Symptoms Shows Significant Discrepancies Between Patients and Physicians
• Bortezomib-Doxorubicin-Dexamethasone (BDD) for Reversal of Acute Light Chain Induced Renal Failure (ARF) in Multiple Myeloma (MM). Results from a Phase II Study
• Bortezomib-Doxorubicin-Dexamethasone (BDD) in Patients with Acute Light Chain Induced Renal Failure (ARF) in Multiple Myeloma (MM). Final Results of a Phase II Study
• CML Patients In Clinical Trials Represent Fairly Well The General Population Of CML Patients: A Comparative Analysis Of 5803 Patients From The EUTOS Registry
• Double Transplantation with Melphalan (200 mg/m2) Compared with Triple Transplantation with Intermediate Dose Melphalan (100 mg/m2) in Patients with Multiple Myeloma
• Early PK-Analysis Predicts Molecular Response In Patients With Early Chronic Phase Chronic Myelogenous Leukemia (CML-CP) Treated With Frontline Nilotinib
• Four Weeks Administration Schedule of Ropeginterferon Alfa-2b (AOP2014/P1101) in Polycythemia Very Patients Allows Maintaining of Efficacy with Favorable Toxicity Profile in the Phase I/II Peginvera Study
• Incidence of CML in Europe - a Comparison of 19 European Countries with US SEER Data
• LENALIDOMIDE-DEXAMETHASONE (LD) AS TREATMENT OF ACUTE CAST NEPHROPATHY-INDUCED RENAL FAILURE (ARF) IN MULTIPLE MYELOMA (MM). A PHASE II STUDY
• Long Term Efficacy and Safety Results and Analysis of Dose Correlations from the Phase I/II Peginvera Study of Ropeginterferon Alfa-2b, a Novel IFNa-2b, in Polycythemia Vera Patient
• Prospective, Randomized Comparison between Double Transplantation (T) with Melphalan (200 mg/m2) and Triple T with Intermediate Dose Melphalan (100 mg/m2) in Patients with Multiple Myeloma (An Interim Analysis)
• Recovery of Renal Impairment by Bortezomib-Doxorubicin-Dexamethasone (BDD) in Multiple Myeloma (MM) Patients with Acute Renal Failure. Results from an Ongoing Phase II Study.
• Rituximab Maintenance after Chemoimmunotherapy Induction in 1st and 2nd Line Improves Progression Free Survival: Planned Interim Analysis of the International Randomized AGMT-CLL8/a Mabtenance Trial
• Rituximab Maintenance Significantly Prolongs Event Free (EFS) and Progression Free Survival (PFS) In Male Patients With Aggressive B-Cell Lymphoma In The NHL13 Study
• Single-Cell Immune Signatures in Patients with Chronic Phase Chronic Myeloid Leukemia (CML) Treated with Nilotinib: An ENEST1st Sub Study
• Switch from Every Two Weeks to Every Four Weeks Administration Schedule of AOP2014, an Innovative Pegylated Interferon Alpha, in Polycythemia Very Patients Allows Maintaining of Efficacy with Improved Toxicity Profile in Phase I/II Study
• THALIDOMIDE-DEXAMETHASONE VERSUS MELPHALAN-PREDNISOLONE AS FIRST LINE TREATMENT IN ELDERLY PATIENTS WITH MULTIPLE MYELOMA: AN INTERIM ANALYSIS
• THE EUTOS POPULATION BASED REGISTRY – INCIDENCES OF CML ACROSS EUROPE
• THE EUTOS POPULATION-BASED REGISTRY: EVALUATION OF BASELINE CHARACTERISTICS AND FIRST TREATMENT CHOICES OF 2983 NEWLY DIAGNOSED CHRONIC MYELOID LEUKEMIA (CML) PATIENTS FROM 20 EUROPEAN COUNTRIES
• TREATMENT WITH NILOTINIB IN EARLY CHRONIC PHASE CML–FIRST RESULTS FROM THE ENEST1ST SUB STUDY CAMN107EIC01